

ASX RELEASE

Volpara signs contract with RadNet

Highlights:

- **Volpara signs contract with Radnet Management, Inc., a subsidiary of RadNet, Inc.**
- **Contract includes Analytics and Risk Pathways, both deployed in the cloud**
- **Risk Pathways to be embedded into eRAD, RadNet's electronic medical record system**
- **Contract incorporates a volume-based model with potential upside**

Wellington, NZ, 4 July 2022: Volpara Health Technologies ("Volpara," "the Group," or "the Company"; ASX:VHT), a global leader in software for the early detection of breast cancer, today announced that it has signed a contract with Radnet Management, Inc. ("RadNet"), for an initial contract period of 42 months, with the mutual option to extend.

RadNet, based in Los Angeles, California, is the largest provider of outpatient imaging services in the United States. RadNet has 9,000 employees and operates across 353 imaging centres in seven states.

The volume-based contract sees RadNet implementing Volpara® Analytics™ and Volpara® Risk Pathways™ software throughout its organisation. Volpara Analytics's artificial intelligence will consistently manage mammography quality across RadNet's 350+ sites. Volpara Risk Pathways provides risk-based screening to ensure RadNet patients have access to essential imaging and genetic testing. Planning for the implementation has begun, with go-live projected in 2023. Management expects that revenue generated under the agreement will be material to the Company.

Volpara Group CEO Teri Thomas said: "Volpara is pleased to partner with such a large and well-respected organisation as RadNet. Together we will save even more families from cancer. This is a broader partnership than a simple software purchase. We look forward to a deep engagement with RadNet as part of our focus on industry impacts and customer success of 'elephant-sized' industry leaders."

Authorisation & Additional Information

This announcement was authorised by the CEO of Volpara Health Technologies Limited.

ENDS

For further information, please contact:

Teri Thomas, CEO

Volpara Health Technologies

teri.thomas@volparahealth.com

t: +64 4 499 6029

Hannah Howlett

WE Communications

WE-AUVolpara@we-worldwide.com

t: +61 407 933 437

About Volpara Health Technologies Limited (ASX:VHT)

Volpara Health Technologies is a global leader in the research and development of artificial intelligence for the early detection of breast cancer. Volpara's software provides clinicians feedback on breast density, compression, dose, and quality, enabling them to offer their patients personalised breast care and enhanced risk assessment.

Founded in 2009 on research originally conducted at the University of Oxford, Volpara has seen its technology and services used by customers and/or research projects in 40 countries. Volpara's groundbreaking work is supported by 100 patents, over 200 peer-reviewed publications, the most rigorous security certifications, and numerous trademarks and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, Volpara has raised A\$132 million. With offices in Seattle and Boston, Volpara is based in Wellington, New Zealand.

For more information, visit www.volparahealth.com.